Allogeneic Transplantation for Acute Myeloid Leukemia in CR1

The advisability of allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia(AML) in first CR(CR1) is an increasingly important subject given the greater ability to safely perform reduced-intensity/non myeloablative HCT in older subjects1 and its extension to unrelated donors. The latter has complicated conventional donor-no donor analyses designed to account for the “guarantee time” HCT recipients, but not chemotherapy-only subjects, must live prior to HCT2. In this issue of BBMT Østgård et al.3 use the more appropriate Mantel-Byar method, crediting to chemotherapy follow-up time prior to HCT2.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research